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Background: Partial hepatectomy with clear surgical margins is the main curative treatment for hepatic
malignancies. The safety of liver resection, to a great extent, depends on the volume of future liver
remnant. This manuscript reviews some important strategies that have been developed to increase
resectability for patients with borderline volume of future liver remnant, particularly associating liver
partition and portal vein ligation for staged hepatectomy (ALPPS).
Methods: To identify potentially relevant articles, we searched Medline and PubMed from January 2010
to December 2013 using the keywords “Associating liver partition and portal vein ligation for staged
hepatectomy”, “ALPPS”, “portal vein embolization”, “future liver remnant”, “liver hypertrophy”, and “liver
failure”. A number of references from the key articles were also cited. There were no exclusion criteria for
published information to the topics.
Results: Portal vein ligation (PVL) or embolization (PVE) are traditional approaches to induce liver hy-
pertrophy of the future liver remnant (FLR) prior to hepatectomy in primarily non-resectable liver tu-
mors. However, about 14 percent of patients fail to this approach. Adequate hypertrophy of the FLR using
PVL or PVE generally takes more than four weeks. ALPPS can induce rapid growth of the FLR, which is
more effective than by portal vein embolization or occlusion alone. Reportedly, the hypertrophy extent of
FLR was 40%e80% within 6e9 days in contrast to approximately 8%e27% within 2e60 days by PVL/PVE.
However, ALPPS was reported to have high operative morbidity (16%e64% of patients), mortality (12%
e23% of patients) and bile leakage rates. Bile leakage and sepsis remain a major cause of morbidity, and
the main cause of mortality includes hepatic insufﬁciency.
Conclusion: ALPPS has emerged as a new strategy to increase resectability of hepatic malignancies. Due
to high morbidity and mortality rates of ALPPS procedure, the surgical candidates should be selected
carefully. Moreover, there are very limited available evidence for its technical feasibility, safety and
oncological outcome which are needed for further evaluation in larger scale of studies.
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Partial hepatectomy with clear surgical margins is the main
curative treatment for primary liver cancer or colorectal liver
metastatses [1]. However, size of future liver remnant (FLR) is one
of the determining factors for resectability as postoperative liver
failure is the most severe complication after partial hepatectomy. Inngji Hospital, Tongji Medical
nology, 1095# Jiefang Road,
en).
by Elsevier Ltd. All rights reservedgeneral, patients without any underlying liver diseases can tolerate
a FLR volume greater than or equal to 25% of the liver volume.
Patients with chronic liver disease but without cirrhosis usually
require a FLR of at least 30% while those patients with cirrhosis but
without portal hypertension require a FLR of at least 40% [2,3].
Truant and her associates [4] recommend an estimated FLR to body
weight ratio of greater than 0.5. Thus, for patients with borderline
volume of FLR, surgeons have difﬁculty to choose either resection of
the hepatic tumor with potential risk of postoperative liver failure
(PHLF) or giving palliative treatment to the patient, such as using
transcatheter arterial chemoembolization or local ablative therapy
to avoid PHLF [5e7]. In recent years, some strategies, such as portal.
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developed to induce liver hypertrophy of the future liver remnant
(FLR) prior to hepatectomy in primarily non-resectable liver tu-
mors. Two staged liver resections have been developed to increase
the resectability for those bilobar liver malignancies. Associating
liver partition and PVL for staged hepatectomy (ALPPS) is a new 2
stage surgical strategies to increase size of FLR. It can induce rapid
liver hypertrophy avoiding liver failure in most patients, so it can
enable resection in patients with liver tumors previously consid-
ered unresectable. However, its safety and effectiveness remain
unclear. In this article, we provide a systematic review of current
status of ALPPS.
2. Traditional strategies to increase resectability
2.1. Preoperative portal vein embolization (PVE)
Makuuchi and his associates [8] ﬁrst introduced the concept of
PVE into clinical practice in the 1980s. For patients with large or
multiple tumors located in right hemiliver and segment 4, the right
portal branch was embolized to induce marked atrophy of the
affected right liver and prominent hypertrophy of the contralateral
left liver. There are many subsequent reports describing the efﬁcacy
of preoperative PVE in extended hepatectomies [9,10]. With ad-
vances in radiological intervention, PVE can now be safely carried
out via one of the following two approaches, the contralateral and
the ipsilateral approaches, using ultrasound-guided percutaneous
transhepatic puncture under local anesthesia. PVE induces liver
hypertrophy by increasing the production of hepatic growth factor
(HGF) and transforming growth factor (TGF), along with redistri-
bution of portal blood ﬂow [11]. Complications after PVE include
liver abscess, biliary ﬁstula, main or branched portal venous
thrombosis or even liver necrosis due to concomitant injury of
hepatic artery [12]. The potential drawbacks are: ﬁrstly, obstructed
bile ducts in the embolized liver segments may get infected and can
develop into troublesome abscesses when resection is not carried
out; secondly, enhanced tumor growth after PVE can be recognized.
Changes in cytokines and growth factors, alterations in hepatic
blood supply and enhanced cellular host response can promote
local tumor growth after PVE; thirdly, patients showing slow
growth of FLR or with persistently small FLR volume after 3 weeks
of PVE are unlikely to exhibit further liver regeneration beyond this
time point. Thus, further extension of the waiting time seems futile
[13]; fourthly, small metastases in the FRL or peritoneal carcino-
matosis can escape detection from medical imaging and are only
detected during laparotomy. A meta-analysis published in 2008 on
37 studies carried out from 1990 to 2005 involving 1088 patients
demonstrated that it took a mean of 29 days from PVE to surgery,
with an 8% to 27% increase in FLR, and in 14% of patients resection
was precluded after PVE due to disease progression or insufﬁcient
hypertrophy of the FLR [12].
2.2. Two-stage hepatectomy
The two-stage hepatectomy was pioneered by surgeons at the
Hôpital Paul Brousse in the 2000s. The operation was designed
when it was impossible to remove all malignant lesions in the liver
in a single procedure [14]. The intention of the ﬁrst hepatectomy
was to keep the ﬁnal FLR clear of all malignant lesions. During the
waiting time to second operation, the FLR hypertrophies can be
induced making the second hepatectomy feasible and potentially
curative [15]. Under this principle, a variety of methods of two-
stage hepatectomy were developed. Jaeck [16] routinely used
right PVE which resulted in hypertrophy of the left liver after the
initial removal of all the tumors located in the left liver (the FLR),allowing a safer curative right or extended-right hemihepatectomy.
Clavien [2] modiﬁed the procedure by combining wedge resections
of all the left-sided tumors in the FLR and concomitant right portal
vein ligation in the ﬁrst operation, and then followed by extended
right hepatectomy a few weeks later. This modiﬁcation is based on
evidences that portal vein ligation triggers a similar or better
regenerative response than PVE [17]. On this basis, Adam and his
colleagues [15] combined ligature or/and absolute alcohol injection
into the right portal vein at time of ﬁrst operation involving
resection of all the left sided malignant lesions in FLR. The ligature
precluded any backﬂow of alcohol into the main/left portal vein as
well as cavernous transformation of the ligated portal system.
These improvements enormously shorten the interval between two
hepatectomies. However, the major reason for failure of the two-
stage hepatectomy is tumor progression during a too long wait-
ing period for the FLR to hypertrophy or an insufﬁcient volume
increase after portal vein occlusion [18e20]. There are other dis-
advantages [21e23]: ﬁrstly, liver regeneration can be impaired or
altered by prolonged use of some chemotherapeutic agents. Sec-
ondly, patients have to be carefully selected to slow tumor pro-
gressionwith well-differentiated tumors allowing a sufﬁcient delay
for regeneration of FLR. Thirdly, in addition to the ﬁbrous adhesions
after the ﬁrst hepatectomy, the atrophyehypertrophy complex
related to the right portal ligation changes the dissection plane of
the right hepatectomy, thus, making it potentially dangerous to
perform the second hepatectomy.
3. The new strategy: ALPPS
3.1. The emergence of ALPPS
Professor Hans Schlitt from Regensburg, Germany, performed
the ﬁrst ALPPS in 2007. To a certain extent, this great procedurewas
invented by chance. Professor Schlitt planned to carry out extended
right hepatectomy in a patient with hilar cholangiocarcinoma. He
realized intraoperatively that the FLR was too small to sustain the
patient’s life postoperatively. Hence, he made a good but uncom-
mon surgical decision by performing only selective left hepatico-
jejunostomy for palliation. For optimal positioning of hepatico-
jejunostomy, he divided liver parenchyma along falciform liga-
ment, thereby completely devascularizing segment 4. He also
ligated right portal vein in order to induce hypertrophy of left
lateral section of liver. Out of curiosity, he performed a computed
tomography scan on postoperative day 8. To his surprise, the left
lateral section had grown enormously in size. He successfully
removed the diseased liver with another operation. This novel
approach was formally reported as a series of 3 cases in a poster
presented by Baumgart et al. [24], fromMainz, Germany, during the
Ninth E-AHPBA Meeting held in Cape Town, South Africa in April
2011. In 2012, de Santibanes [25] and Clavien proposed the acronym
“ALPPS”(associating liver partition and portal vein ligation for
staged hepatectomy) for this novel technique. Here, what is worth
mentioning is that the similar idea had been put forward by Prof.
Chen [26] in 1985, and he pointed out that it would be secure to
have the graft removed once the autologous liver meet physiolog-
ical need for auxiliary partial liver transplantation.
3.2. The characteristics of ALPPS
ALPPS has recently been described as a new strategy to induce a
rapid and large FLR volume increase. There are two important
characteristics of ALPPS: rapid hypertrophy and fundamental
auxiliary role undertaken by deportalized and diseased liver during
time interval between in situ liver splitting (ISLS) and second
operation. Although the arterialized liver containing tumor is
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auxiliary liver to assist the growing FLR in metabolic, synthetic, and
detoxifying functions until the contralateral liver has grown
enough to entirely take up the physiological function [27,28]. It is at
this time that the deportalized part of liver can be removed with
impunity. The reported mean interval between the ﬁrst and the
second operation was 7 days (range: 6e9 days). The evidence just
depends on those cohort series in heterogenous group of patients.
All these studies are mainly focused on hypertrophy rate, technical
feasibility and safety.
PVL or PVE are traditional approaches to induce liver hyper-
trophy of the FLR prior to hepatectomy in primarily non-
resectable liver tumors. However, these approaches fail in about
14 percent of patients. Adequate hypertrophy of FLR using PVL or
PVE generally takes more than four weeks. Although the growth
rate after PVE can be increased by portal CD133-positive stem cell
application, this still cannot grow as fast as the FLR hypertrophy
after ISLS. ALPPS can induce rapid growth of FLR, which is greater
than that of reported with portal vein embolization or occlusion
alone. Recent studies have conﬁrmed marked hypertrophy of FLR
by 40%e80% within 6e9 days or 22% per day after ISLS compared
with approximately 3% after PVE [29]. In addition, Knoefel and his
associates [30] demonstrated that ISLS can offer an opportunity
for curative liver resection even after failed PVE with insufﬁcient
growth of FLR. ISLS leads to complete devascularization of
segment 4 and prevents formation of vascular collaterals between
left lateral section and remaining right sided liver, leading to
portal ﬂow deprivation to excluded segments 2 and 3and redis-
tribution of hepatotrophic factors, resulting in accelerated liver
hypertrophy [31,2]. Knoefel [30] showed that rapid growth of FLR
after ISLS is a result of real parenchymal hypertrophy because
there are only small differences on the density of FLR on CT im-
ages carried out before and 3 days after ISLS. Thanks to faster
hepatocyte regeneration, drop-out rate of two-stage procedure
become less. This waiting time interval can be critical, especially
for patients with marginally resectable tumors or oncologically
aggressive tumors [33]. Furthermore, ALPPS allows earlier post-
operative chemotherapy.
3.3. Indications and contraindications of ALPPS
The indications of ALPPS include patients with FLR of less than
30% in normal livers or less than 40% in diseased livers resulting
from cholestasis, macrosteatosis, ﬁbrosis or pathologic changes
associated with chemotherapy. Indications include marginally
resectable or locally advanced unresectable liver tumors of any
origin with an insufﬁcient FLR either in volume or quality. The
pathologies that commonly applied include colorectal liver me-
tastases, hilar cholangiocarcinoma and hepatocellular carcinoma.
In addition, major liver resection combined with synchronous
resection of other organs, such as colorectal cancer and liver me-
tastases, neuroendocrine pancreatic and intestinal tumors with
massive liver metastases, are also potential indications. ALPPS is
mainly applicable to those who needed extended right hepatec-
tomy. The contraindications of ALPPS include unresectable liver
metastases in the FLR, unresectable extrahepatic metastases, severe
portal hypertension, high anesthetic risks, poor medical conditions
for major surgery [34].
3.4. Operative steps in ALPPS
The morbidity and mortality rates after ALPPS have been re-
ported by Torres and his associates [35] to be 59.0% and 12.8%,
respectively.With the advances in surgical techniques, 0% operative
mortality rates have been reported [32,34e36]. It is important toidentify proper disease staging by intraoperative exploration and
intraoperative ultrasound (IOUS). Dissection of the hepatoduodenal
ligament and radical lymphadenectomy should be performed not
only for oncological reasons. Clear identiﬁcation of all hilar struc-
tures is necessary for such a complex procedure. The right liver is
completely mobilized from the inferior vena cava (IVC). The right
portal vein is ligated. It is of paramount importance to avoid any
damage to hepatic artery of diseased liver and to the vasculobiliary
structures of FLR. Hepatic parenchymal transection is carried out on
right side of falciform ligament, separating liver segments 2 and 3
from the rest of liver. Cholangiography is routinely performed
through cystic duct after liver parenchymal transection to detect
any bile leak. At the end of the ﬁrst operation, the hepatic pedicle of
diseased liver, the hepatic veins, and the cystic duct are encircled
with a black silk to facilitate their identiﬁcation during second stage
of the operation. The use of ﬁbrin sealant on the raw surface or a
plastic bag around the liver facilitates the second procedure by
minimizing postoperative adhesions and avoiding bile peritonitis
due to bile leak. Prophylactic antibiotics are given because of the
presence of an ischemic diseased liver and a foreign body in the
abdominal cavity. In the second stage of the operation, intra-
operative ultrasound is used on the FLR to detect any tumor that
might have been missed during the ﬁrst operation. If new tumors
are found, either resection or ablative therapy can be performed.
Resection of the diseased liver is achieved using vascular staplers
for the vasculobiliary structures. There are some important points
on this operation: ﬁrst, preoperative chemotherapy does not seem
to inﬂuence the degree of liver hypertrophy [32]. Second, simul-
taneous surgery for primary tumor with ALPPS on synchronous
liver metastases has been shown to be safe and effective in the ﬁrst
stage operation [34]. Third, total laparoscopic ALPPS has been re-
ported [35,37] with effect of less adhesions during the second stage
of operation [35,37]. Fourth, ligation of bile duct of the diseased
liver does not improve the degree of liver hypertrophy, but in-
creases morbidity and mortality due to bile leak with possible
injury of right hepatic artery during dissection [38].3.5. The modiﬁcations of ALPPS
In 2013, Gauzolino and his associates [39] presented 3 technical
modiﬁcations of classical ALPPS: the left, the rescue and the right
ALPPS modiﬁcations.
The left ALPPS modiﬁcation: The ﬁrst step consists of limited
resection or anatomical segmentectomy of the right anterior and
posterior sections, left PVL and ISLS between the right and left
livers along the main portal ﬁssure. The second surgical step con-
sists of completing the left hemihepatectomy with resection of
segment 1.
The rescue ALPPS modiﬁcation: The ﬁrst step consists of ISLS
between the right and left hemilivers along the main portal ﬁssure;
the right portal vein has already been ‘‘ligated’’ by radiological coils.
The second surgical step consists of completing the right hepa-
tectomy. This modiﬁcation is limited to patients who are not can-
didates for the second step of ‘‘classical’’ two-stage hepatectomy
because of insufﬁcient liver hypertrophy after the conventional
methods.
The right ALPPSmodiﬁcation: The ﬁrst surgical step consists of a
left lateral sectionectomy, ligation of the posterolateral branch of
the right portal vein, multiple limited or anatomical resections of
the left medial, right anterior section and caudate lobe. ISLS along
the right portal ﬁssure is facilitated by a right modiﬁed hanging
maneuver positioning the lower end of hanging tape between the
anterior and posterior right pedicles. The second step consists of
completing the right posterior sectionectomy.
Table 1
Reported outcomes of ALPPS.
Institute Years Case no. Volume
Increase (%)
Complete
Surgery (%)
R0 resection
(%)
Hepatic
insufﬁciency (%)
Sepsis
(%)
Bile leakage
(%)
Morbidity
(%)
In-hospital
mortality (%)
Schnitzbauer et al. [32] Single 2012 25 74 (median) 88 100 e 20 24 64 12
Sala et al. [27] Single 2012 10 82 (mean) 100 100 20 e 20 40 0
Li et al. [29] Single 2013 9 87 (median) 100 100 22 22 22 16 22
Clavien et ala Single 2013 13 e 100 100 15 23 e e 23
Alvarez et al. [34] Single 2013 15 78 (mean) 100 100 20 20 20 53 0
Torres et al. [35] Single 2013 39 83 (mean) 94.9 100 2.5 7.7 10.2 59 12.8
ALPPS is a new strategy to increase resectability of hepatic malignancies because it can induce rapid growth of the FLR at short intervals. However, ALPPS was reported to have
high operative morbidity (16%e64% of patients), mortality (12%e23% of patients) and bile leakage rates (10.2%e24% of patients). Bile leakage and sepsis remain a major cause
of morbidity, and the main cause of mortality includes hepatic insufﬁciency.
a The 8th International Meeting of Hepatocellular Carcinoma.
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ALPPS was reported to have high operative morbidity, mortality
and bile leakage rates (Table 1). Morbidity after ALPPS was reported
to be 16%e64% of patients, and the mortality rate was 12%e23% of
patients. The main morbidity included bile leakage and sepsis, and
the main cause of mortality included hepatic insufﬁciency. Another
disadvantage of ALPPS is the use of foreign bodies such as plastic
bags or sheets during the ﬁrst stage of operation. If the second stage
of operation cannot be performed for any reasons, the patients still
need a reoperation to remove the foreign bodies.
In order to answer the questions whether standard two-stage
hepatectomy with intervening percutaneous portal vein emboli-
zation is a better treatment option than ALPPS, Alioa and his as-
sociates [40] believed that the liver hypertrophy rate of patients
with ISLS was similar to the liver hypertrophy rate after percuta-
neous ipsilateral portal vein embolization when extended to
segment 4 using embolic microspheres and coils. They further
argued that standard two-stage hepatectomy with portal vein
embolization has lower operative morbidity and mortality rates
and more appropriate patient selection for second-stage operation,
thus improving the safety and oncological efﬁcacy for second-stage
major hepatectomy.
The long-term oncological outcomes following ALPPS are not
yet available, but the 5-year overall survival after standard two-
stage hepatectomy was reported to be 51%. Dokmak and his asso-
ciates [38] believed that the need for portal vein ligation in ALPPS
requires dissection of the hilar pedicle which is against the prin-
ciple of the “no touch” oncological concept. ALPPS has been suc-
cessfully carried out on a patient with hepatic ﬁbrosis due to
hepatitis C infection with portal vein thrombosis [41]. However,
more studies are needed to evaluate the role of ALPPS in patients
with hepatic ﬁbrosis.
4. Conclusion
ALPPS is a new strategy to increase resectability of hepatic
malignancies. Due to high morbidity and mortality rates related to
ALPPS procedure, the surgical candidates should be selected care-
fully. Current evidence still appears too limited, its technical
feasibility, safety and oncological outcome still need to be evaluated
further in larger scale of studies.
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